2020 Guideline: BPH (2020)

AUA - American Urological Association
8/13/20, 9:00 PM
America/New York GMT -4 summer

Description

The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved dramatically over the past 5 years with changing algorithms. The AUA BPH Guidelines were revised in 2018 focusing primarily on diagnostic algorithms and surgical modalities. The 2020 Guidelines will incorporate recommendations about medical therapies. This course is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS. This will include risk factors such as obesity, the role of both AUA and international guidelines, established algorithms, medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, beta - 3 agonists, 5-alpha reductase inhibitors, PDE - 5 inhibitors and surgical options including minimally invasive (UroLift / Rezum) and surgical options (electrosurgical, laser, aquablation). In addition, how these agents dovetail with sexual function and testosterone replacement therapy will be highlighted. Finally, pharmaco economics and the impact of long term therapy as well as surgical outcomes will be debated.

 

Please note this course is FREE to all AUA Members and is an exclusive member benefit.  If you would like to become an AUA Member, we'd be happy to have you - think about all the great member benefits!

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Steven A. Kaplan

2020 Guideline: BPH (2020)

Inglês

 

Speakers

Steven A. Kaplan